Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.
Follow INBS
Intelligent Bio Solutions Inc. (INBS) Altman Z-score
Intelligent Bio Solutions Inc.'s Altman Z-score for fiscal 2026 is −11.40, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −11.40 | 2.29 |
| FY2025 | −13.69 | (6.77) |
| FY2024 | −6.92 | 2.54 |
| FY2023 | −9.46 | (5.33) |
| FY2022 | −4.12 | (6.26) |
| FY2021 | 2.14 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.18 | — | 0.22 | |
| Retained earnings / total assets | (6.28) | — | −8.79 | |
| EBIT / total assets | (1.06) | — | −3.48 | |
| Market value of equity / total liabilities | 0.51 | — | 0.30 | |
| Sales / total assets | 0.35 | — | 0.35 | |
| Altman Z-score | Distress zone | −11.40 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −25.53 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| WOK WORK Medical Technology Group LTD compare | 1,088× |
| TRIB Trinity Biotech PLC compare | −2.8× |
| TBIO Telesis Bio Inc. compare | −4.5× |
| VVOS Vivos Therapeutics, Inc. compare | −9.1× |
| CODX Co-Diagnostics, Inc. compare | −9.7× |
| INBS Intelligent Bio Solutions Inc. | −11.4× |
| NVNO enVVeno Medical Corporation compare | −28.3× |
| VNRX VolitionRX Limited compare | −62.8× |
| AMIX Autonomix Medical, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets